Hamid Rahmani1, Hossein Khalili1.
Abstract
PURPOSE: This paper aims to review clinical and preclinical evidence regarding new strategies for the prevention of vancomycin-induced nephrotoxicity.
METHODS: Evidence from 2014 to the end of 2019 was included. Twelve animal studies and one clinical trial were evaluated.
RESULTS: Although the incidence of vancomycin-induced nephrotoxicity was not reduced significantly in the clinical trial, antioxidants reduced the incidence of vancomycin-induced nephrotoxicity in preclinical studies.
CONCLUSION: Antioxidants including vitamin C, vitamin E, cilastatin, melatonin, zingerone, rutin, naringenin, saffron, silymarin, and dexmedetomidine were nephroprotective against vancomycininduced nephrotoxicity in preclinical studies. The nephroprotective effects of these antioxidants must be confirmed before routine use in clinical practice. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
PURPOSE: This paper aims to review clinical and preclinical evidence regarding new strategies for the prevention of vancomycin-induced nephrotoxicity.
METHODS: Evidence from 2014 to the end of 2019 was included. Twelve animal studies and one clinical trial were evaluated.
RESULTS: Although the incidence of vancomycin-induced nephrotoxicity was not reduced significantly in the clinical trial, antioxidants reduced the incidence of vancomycin-induced nephrotoxicity in preclinical studies.
CONCLUSION: Antioxidants including vitamin C, vitamin E, cilastatin, melatonin, zingerone, rutin, naringenin, saffron, silymarin, and dexmedetomidine were nephroprotective against vancomycininduced nephrotoxicity in preclinical studies. The nephroprotective effects of these antioxidants must be confirmed before routine use in clinical practice. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Entities:
Keywords:
Vancomycin; kidney injury; nephroprotective; nephrotoxicity; prevention; renal damage; renoprotective
Mesh：
Substances：
Year: 2022
PMID： 33797371 DOI： 10.2174/1871526521666210331164552
Source DB: PubMed Journal: Infect Disord Drug Targets ISSN： 1871-5265